Literature DB >> 27628191

Ten-year survival in women with primary stage IV breast cancer.

Lee Guek Eng1, Shaheenah Dawood2, Victoria Sopik3, Benjamin Haaland4,5, Pui San Tan4, Nirmala Bhoo-Pathy6, Ellen Warner7, Javaid Iqbal3, Steven A Narod3, Rebecca Dent8.   

Abstract

PURPOSE: To evaluate breast cancer-specific survival at 10 years in patients who present with primary stage IV breast cancer, and to determine whether survival varies with age of diagnosis.
METHODS: We retrieved the records of 25,323 women diagnosed with primary stage IV breast cancer in the surveillance, epidemiology, and end results 18 registries database from 1990 to 2012. For each case, we extracted information on age at diagnosis, tumour size, nodal status, oestrogen receptor status, progesterone receptor status, ethnicity, cause of death and date of death. The Cox proportional hazards model was used to estimate the unadjusted and adjusted hazard ratio (HR) of death due to stage IV breast cancer, according to age group.
RESULTS: Among 25,323 women with stage IV breast cancer, 2542 (10.0 %) were diagnosed at age 40 or below, 5562 (22.0 %) were diagnosed between ages 41 and 50 and 17,219 (68.0 %) were diagnosed between ages 51 and 70. After a mean follow-up of 2.2 years, 16,387 (64.7 %) women died of breast cancer (median survival 2.3 years). The ten-year actuarial breast cancer-specific survival rate was 15.7 % for women ages 40 and below, 14.9 % for women ages 41-50 and 11.7 % for women ages 51 to 70 (p < 0.0001). In an adjusted analysis, the risk of death from breast cancer at 10 years was significantly lower for women ages 40 and below (HR 0.78; 95 % CI 0.74-0.82; p < 0.0001) and for women ages 41-50 (HR 0.82; 95 % CI 0.79-0.85; p < 0.0001), compared to women ages 51-70.
CONCLUSIONS: Approximately 13 % of women with primary stage IV breast cancer survive 10 years after diagnosis. Women diagnosed with stage IV breast cancer before age 50 have better survival at 10 years compared to older women.

Entities:  

Keywords:  10-year survival; Primary stage IV breast cancer; Prognosis; SEER database; Young age

Mesh:

Year:  2016        PMID: 27628191     DOI: 10.1007/s10549-016-3974-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  42 in total

1.  Assessing the effect of data integration on predictive ability of cancer survival models.

Authors:  Yi Guo; Jiang Bian; Francois Modave; Qian Li; Thomas J George; Mattia Prosperi; Elizabeth Shenkman
Journal:  Health Informatics J       Date:  2019-01-23       Impact factor: 2.681

2.  Wherein the authors attempt to minimize the confusion generated by their study "Breast cancer mortality after a diagnosis of ductal carcinoma in situ" by several commentators who disagree with them and a few who don't: a qualitative study.

Authors:  S A Narod; H Ahmed; V Sopik
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

3.  Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.

Authors:  Kaitlin Christopherson; Xiudong Lei; Carlos Barcenas; Thomas A Buchholz; Naveen Garg; Karen E Hoffman; Henry Mark Kuerer; Elizabeth Mittendorf; George Perkins; Simona F Shaitelman; Grace L Smith; Michael Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Benjamin D Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-06       Impact factor: 7.038

4.  Surgery and survival in patients with stage IV breast cancer.

Authors:  Cletus Arciero; Yuan Liu; Theresa Gillespie; Preeti Subhedar
Journal:  Breast J       Date:  2019-05-13       Impact factor: 2.431

5.  Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.

Authors:  Hauke Stamm; Leticia Oliveira-Ferrer; Eva-Maria Grossjohann; Jana Muschhammer; Vanessa Thaden; Franziska Brauneck; Roman Kischel; Volkmar Müller; Carsten Bokemeyer; Walter Fiedler; Jasmin Wellbrock
Journal:  Oncoimmunology       Date:  2019-10-12       Impact factor: 8.110

Review 6.  Vascularized Biomaterials to Study Cancer Metastasis.

Authors:  Katharine R Bittner; Juan M Jiménez; Shelly R Peyton
Journal:  Adv Healthc Mater       Date:  2020-01-24       Impact factor: 9.933

Review 7.  Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  B M Aarts; F M Gómez Muñoz; H Wildiers; V O Dezentjé; T R Baetens; W Schats; M Lopez-Yurda; R C Dresen; B J de Wit-van der Veen; C M Deroose; G Maleux; R G H Beets-Tan; E G Klompenhouwer
Journal:  Cardiovasc Intervent Radiol       Date:  2021-07-28       Impact factor: 2.740

8.  NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis.

Authors:  Mengting Chen; Yang Zhao; Xueli Yang; Yuanyuan Zhao; Qiqi Liu; Yang Liu; Yifeng Hou; Hefen Sun; Wei Jin
Journal:  Breast Cancer Res Treat       Date:  2021-04-16       Impact factor: 4.872

9.  Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival.

Authors:  Peter Schullian; Edward Johnston; Gregor Laimer; Daniel Putzer; Gernot Eberle; Yannick Scharrl; Claudia Ianetti-Hackl; Reto Bale
Journal:  Cardiovasc Intervent Radiol       Date:  2021-04-06       Impact factor: 2.740

10.  Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.

Authors:  Yi-Zi Zheng; Xian-Ming Wang; Lei Fan; Zhi-Ming Shao
Journal:  Oncologist       Date:  2020-11-03       Impact factor: 5.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.